RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiabowelchemotherapytherapypatient
  Phrases that lowered it: aminotransferaseimpairmentsafety ofbreastmg
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: 23.3% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Keywords listed: 18 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 159 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 18.6% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 96128 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 23289 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 210 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports marked serious: 80.0% (lowers risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas NCT01567475 · started 2011 · scored riskier than 71% of active trials completed
• Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies NCT01182168 · started 2010 · scored riskier than 28% of active trials completed
• RAD001 Plus Carboplatin in Breast Cancer Patients NCT01127763 · started 2010 · scored riskier than 96% of active trials completed
• Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma NCT01510119 · started 2011 · scored riskier than 99% of active trials completed
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy NCT00790036 · started 2009 · scored riskier than 51% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.